Cargando…

Extreme Oncoplasty: Breast Conservation in Patients with Large, Multifocal, and Multicentric Breast Cancer

INTRODUCTION: Extreme Oncoplastic Breast Conservation Surgery (EOBCS) is offered in selected patients with multifocal or multicentric breast cancer (MFMC). Recent evidence has suggested that EOBCS may be a valuable resource for patients with MFMC who may avoid the risk associated with mastectomy in...

Descripción completa

Detalles Bibliográficos
Autores principales: Savioli, Francesca, Seth, Subodh, Morrow, Elizabeth, Doughty, Julie, Stallard, Sheila, Malyon, Andy, Romics, Laszlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164874/
https://www.ncbi.nlm.nih.gov/pubmed/34079367
http://dx.doi.org/10.2147/BCTT.S296242
_version_ 1783701209207537664
author Savioli, Francesca
Seth, Subodh
Morrow, Elizabeth
Doughty, Julie
Stallard, Sheila
Malyon, Andy
Romics, Laszlo
author_facet Savioli, Francesca
Seth, Subodh
Morrow, Elizabeth
Doughty, Julie
Stallard, Sheila
Malyon, Andy
Romics, Laszlo
author_sort Savioli, Francesca
collection PubMed
description INTRODUCTION: Extreme Oncoplastic Breast Conservation Surgery (EOBCS) is offered in selected patients with multifocal or multicentric breast cancer (MFMC). Recent evidence has suggested that EOBCS may be a valuable resource for patients with MFMC who may avoid the risk associated with mastectomy in favour of the benefits of breast conservation without risking their oncological outcomes. Our study examined the practice of EOBCS in two regional breast units in Glasgow, United Kingdom. MATERIALS AND METHODS: A prospectively collected database of 50 patients treated with EOBC in two breast units in Glasgow between 2007 and 2018 were evaluated, and clinical outcomes were observed. RESULTS: Fifty patients (median age 55) underwent EOBCS, of which 43 (86%) had invasive disease. Median tumour size was 55mm (50–90) and multifocal disease was identified in 22 (44%) patients. Nine patients (18%) were found to have positive margins and underwent a second procedure, with 6 (12%) proceeding to mastectomy. Five-year disease free survival rate was 91.5%, while cancer-specific survival was 95.7%. CONCLUSION: EOBCS is oncologically safe in short-term follow-up. Large scale studies are required to confirm these preliminary results, in order to offer EOBCS as a valid option to patients with advanced or multifocal breast cancer.
format Online
Article
Text
id pubmed-8164874
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-81648742021-06-01 Extreme Oncoplasty: Breast Conservation in Patients with Large, Multifocal, and Multicentric Breast Cancer Savioli, Francesca Seth, Subodh Morrow, Elizabeth Doughty, Julie Stallard, Sheila Malyon, Andy Romics, Laszlo Breast Cancer (Dove Med Press) Original Research INTRODUCTION: Extreme Oncoplastic Breast Conservation Surgery (EOBCS) is offered in selected patients with multifocal or multicentric breast cancer (MFMC). Recent evidence has suggested that EOBCS may be a valuable resource for patients with MFMC who may avoid the risk associated with mastectomy in favour of the benefits of breast conservation without risking their oncological outcomes. Our study examined the practice of EOBCS in two regional breast units in Glasgow, United Kingdom. MATERIALS AND METHODS: A prospectively collected database of 50 patients treated with EOBC in two breast units in Glasgow between 2007 and 2018 were evaluated, and clinical outcomes were observed. RESULTS: Fifty patients (median age 55) underwent EOBCS, of which 43 (86%) had invasive disease. Median tumour size was 55mm (50–90) and multifocal disease was identified in 22 (44%) patients. Nine patients (18%) were found to have positive margins and underwent a second procedure, with 6 (12%) proceeding to mastectomy. Five-year disease free survival rate was 91.5%, while cancer-specific survival was 95.7%. CONCLUSION: EOBCS is oncologically safe in short-term follow-up. Large scale studies are required to confirm these preliminary results, in order to offer EOBCS as a valid option to patients with advanced or multifocal breast cancer. Dove 2021-05-25 /pmc/articles/PMC8164874/ /pubmed/34079367 http://dx.doi.org/10.2147/BCTT.S296242 Text en © 2021 Savioli et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Savioli, Francesca
Seth, Subodh
Morrow, Elizabeth
Doughty, Julie
Stallard, Sheila
Malyon, Andy
Romics, Laszlo
Extreme Oncoplasty: Breast Conservation in Patients with Large, Multifocal, and Multicentric Breast Cancer
title Extreme Oncoplasty: Breast Conservation in Patients with Large, Multifocal, and Multicentric Breast Cancer
title_full Extreme Oncoplasty: Breast Conservation in Patients with Large, Multifocal, and Multicentric Breast Cancer
title_fullStr Extreme Oncoplasty: Breast Conservation in Patients with Large, Multifocal, and Multicentric Breast Cancer
title_full_unstemmed Extreme Oncoplasty: Breast Conservation in Patients with Large, Multifocal, and Multicentric Breast Cancer
title_short Extreme Oncoplasty: Breast Conservation in Patients with Large, Multifocal, and Multicentric Breast Cancer
title_sort extreme oncoplasty: breast conservation in patients with large, multifocal, and multicentric breast cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164874/
https://www.ncbi.nlm.nih.gov/pubmed/34079367
http://dx.doi.org/10.2147/BCTT.S296242
work_keys_str_mv AT saviolifrancesca extremeoncoplastybreastconservationinpatientswithlargemultifocalandmulticentricbreastcancer
AT sethsubodh extremeoncoplastybreastconservationinpatientswithlargemultifocalandmulticentricbreastcancer
AT morrowelizabeth extremeoncoplastybreastconservationinpatientswithlargemultifocalandmulticentricbreastcancer
AT doughtyjulie extremeoncoplastybreastconservationinpatientswithlargemultifocalandmulticentricbreastcancer
AT stallardsheila extremeoncoplastybreastconservationinpatientswithlargemultifocalandmulticentricbreastcancer
AT malyonandy extremeoncoplastybreastconservationinpatientswithlargemultifocalandmulticentricbreastcancer
AT romicslaszlo extremeoncoplastybreastconservationinpatientswithlargemultifocalandmulticentricbreastcancer